ROLE OF VITAMIN C IN MANAGEMENT OF COVID 19

Phase 3

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2020/11/029230
• Lead Sponsor: I

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

All patients above the age of 18 years both males and females, admitted with a diagnosis of

Moderate & Severe COVID -19 (on the basis of a positive RT-PCR report) at our facility during the

study period (16/08/2020-15/12/2020)

Exclusion Criteria

1. Patients with a known allergy to or adverse drug reaction with vitamin C.

2. Patients unable to provide consent or unwilling to participate in the study.

3. Patients participating in any other ongoing clinical trial will be excluded from the study.

4. Patients below the age of 18 years will be excluded from the study.

5. Pregnant or Breastfeeding Females will be excluded from the study.

6.Patients previously complicated with End-stage Lung Disease, End stage Malignancy, Glucose-6-

Phosphate dehydrogenase deficiency, Diabetes Mellitus & Diabetic Ketoacidosis , Nephrolithiasis,

Chronic Kidney Disease, Cardiogenic Pulmonary Edema will be Excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Clinical Recovery From the disease . <br/ ><br>2. In Hospital Mortality .Timepoint: AT WEEKLY INTERVA

Secondary Outcome Measures

Name	Time	Method
1. Improvement in Organ Failure Scores (APACHE & qSOFA Scores.). <br/ ><br>2. Fall In level of Inflammatory Markers. <br/ ><br>3. Improvement in Respiratory Index. <br/ ><br>4. Duration on Mechanical ventilator. <br/ ><br>5. Duration on Vasopressor Therapy.Timepoint: AT WEEKLY INTERVA